Last reviewed · How we verify

NCT06701214: CHIVE

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

Recruiting now Last updated 22 November 2024
What this trial tests

trial testing Blood collection in Clonal Hematopoiesis in 800 participants. Currently enrolling.

Timeline
28 October 2020
Primary endpoint
30 November 2030
30 November 2031

Quick facts

Lead sponsorVanderbilt-Ingram Cancer Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment800
Start date28 October 2020
Primary completion30 November 2030
Estimated completion30 November 2031
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

18 and older, any sex, with Clonal Hematopoiesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood collection

Trials testing the same drug.

Other recruiting trials for Clonal Hematopoiesis

Currently open trials in the same condition.

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06701214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing